A Strategy for Eliciting Antibodies against Cryptic, Conserved, Conformationally Dependent Epitopes of HIV Envelope Glycoprotein

Abstract

BackgroundNovel strategies are needed for the elicitation of broadly neutralizing antibodies to the HIV envelope glycoprotein, gp120. Experimental evidence suggests that combinations of antibodies that are broadly neutralizing in vitro may protect against challenge with HIV in nonhuman primates, and a small number of these antibodies have been selected by repertoire sampling of B cells and by the fractionation of antiserum from some patients with prolonged disease. Yet no additional strategies for identifying conserved epitopes, eliciting antibodies to these epitopes, and determining whether these epitopes are accessible to antibodies have been successful to date. The defining of additional conserved, accessible epitopes against which one can elicit antibodies will increase the probability that some may be the targets of broadly neutralizing antibodies.Methodology/Principal FindingsWe postulate that additional cryptic epitopes of gp120 are present, against which neutralizing antibodies might be elicited even though these antibodies are not elicited by gp120, and that many of these epitopes may be accessible to antibodies should they be formed. We demonstrate a strategy for eliciting antibodies in mice against selected cryptic, conformationally dependent conserved epitopes of gp120 by immunizing with multiple identical copies of covalently linked peptides (MCPs). This has been achieved with MCPs representing 3 different domains of gp120. We show that some cryptic epitopes on gp120 are accessible to the elicited antibodies, and some epitopes in the CD4 binding region are not accessible. The antibodies bind to gp120 with relatively high affinity, and bind to oligomeric gp120 on the surface of infected cells.Conclusions/SignificanceImmunization with MCPs comprised of selected peptides of HIV gp120 is able to elicit antibodies against conserved, conformationally dependent epitopes of gp120 that are not immunogenic when presented as gp120. Some of these cryptic epitopes are accessible to the elicited antibodies.

Strategies in the development of vaccines to prevent infections with group A streptococcus

“…The strategy to identify this cryptic epitope may be applicable to vaccine development for other organisms. 24,25 Our specific approach was to focus on the carboxyl-terminal region of the M protein, a major virulence factor for the organism. There was evidence that this relatively large but highly conserved carboxyl-terminal segment of the protein was capable of inducing protection in a mucosal challenge model.…”

Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy

“…Targeting of the conformational epitope has been more actively pursued in immunologic circles. In a recent study, Kelker and colleagues (44) showed that careful immunogen selection resulted in the generation of antibodies with promising therapeutic potential. By targeting cryptic, usually conserved epitopes in the gp120 protein of HIV, they also showed strong parallels with the development and therapeutic paradigm of mAb 806.…”

Constitutive Production of Catalytic Antibodies to a Staphylococcus aureus Virulence Factor and Effect of Infection

“…Adaptive production of such antibodies would obscure the infection-induced effect on the constitutive binding of the B-SAg determinant. For example, HIV infection induces a vigorous antibody response to the immunodominant gp120 epitopes, even as there is no appreciable antibody response to the B-SAg determinant of this protein (60,62). We suggest that the observed post-infection decrease of Efb cleaving activity accurately reflects the infection-induced antibody response directed solely to the putative B-SAg determinant.…”